Randomized human trial · Evidence assessment
How large was the magnesium bisglycinate sleep result?
The trial found a small additional improvement in reported insomnia symptoms over four weeks. It did not establish an objective sleep benefit or superiority to other magnesium forms.
Longevity Lab Report · Assessed · Main study published 2025-08-30
Claim being examined
Magnesium bisglycinate improves sleep in adults who report poor sleep.
This page assesses the named study and relevant context. It is not a complete systematic review or an individual medical assessment.
What the study measured
- Population
- 155 adults aged 18–65 with self-reported poor sleep.
- Study design
- Randomized, double-blind, placebo-controlled trial.
- What was tested
- Magnesium bisglycinate providing 250 mg elemental magnesium daily; this describes the trial, not a suggested dose.
- Comparison
- Placebo capsules.
- Duration
- Four weeks.
- Measured outcome
- Change in the Insomnia Severity Index, a questionnaire.
- Observed result
- Scores fell 3.9 points with magnesium and 2.3 with placebo. The additional decrease was 1.6 points; P=0.049 and reported effect size d=0.2.
- Safety limits
- Four weeks of observation cannot establish long-term safety.
- Funding and disclosures
- University-funded. One author disclosed leading a research organization that receives nutraceutical-company funding.
What limits the conclusion?
- Questionnaires measure reported symptoms, not sleep stages or minutes measured in a laboratory.
- The small, short trial did not compare magnesium forms.
- Baseline magnesium status was not directly measured.
Prior and related evidence
An earlier trial in 46 older adults studied magnesium for eight weeks. A 2021 systematic review of three small trials found low or very low certainty evidence, with outcomes not consistently improved.
The source list below distinguishes the main study from context.
What this evidence added
This 2025 trial adds evidence specifically about bisglycinate in a broader adult age range.
What it did not establish
A small questionnaire change does not establish a general treatment for insomnia. The current assessment does not rank forms or recommend a regimen.
Still unknown
- Whether the result persists with longer use or replicates.
- Whether glycine, magnesium or their combination accounts for the observed effect.
Does this study address your question?
Optionally compare the population, intervention and outcome. These are study comparisons, not medical advice or a treatment recommendation. Your answers stay on this page and are not saved or included in sharing.
Keep the evidence available
Open the public card to print or shareSaved in this browser only. No account or email required.
Assessment history
· Baseline assessment
First entry in this evidence history. This is a dated assessment of existing research, not a newly published study or a change to a library grade.
Conclusion changed: not applicable — no earlier version in this history.
Sources: bisglycinate · older-adults · review
Sources
- Bisglycinate sleep trial (Schuster et al., 2025)
Main study · Published 2025-08-30 · Checked 2026-11-15 · PMID 40918053
Primary publication results, limitations and disclosures via indexed PMC and publisher text
- Magnesium insomnia trial (Abbasi et al., 2012)
Context · Published 2012-12 · Checked 2026-11-15 · PMID 23853635
Primary publication abstract and indexed results
- Systematic review (Mah and Pitre, 2021)
Context · Published 2021-04-17 · Checked 2026-11-15 · DOI 10.1186/s12906-021-03297-z
Original systematic review, indexed full text
Follow the research in the newsletter
Read the week’s longevity reporting and evidence assessments. Your watchlist and comparison answers are separate from your subscription.
Free. Unsubscribe anytime.
Every grade follows a published rubric. Sponsors do not influence findings or grades.